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Abstract
Introduction: MicroRNAs (miRNAs) are small, non-coding, single-stranded RNAs between 18-22 nucleotides long
that regulate gene expression. Expression of miRNAs is altered in tumor compared to normal tissue; there is some
evidence that these changes may be reflected in the serum of cancer cases compared to healthy individuals.
This has yet to be examined in a prospective study where samples are collected before diagnosis.
Methods: We used Affymetrix arrays to examine serum miRNA expression profiles in 410 participants in the Sister
Study, a prospective cohort study of 50,884 women. All women in the cohort had never been diagnosed with
breast cancer at the time of enrollment. We compared global miRNA expression patterns in 205 women who
subsequently developed breast cancer and 205 women who remained breast cancer-free. In addition within the
case group we examined the association of miRNA expression in serum with different tumor characteristics,
including hormone status (ER, PR, and HER-2) and lymph node status.
Results: Overall, 414 of 1,105 of the human miRNAs on the chip were expressed above background levels in 50 or
more women. When the average expression among controls was compared to cases using conditional logistic
regression, 21 miRNAs were found to be differentially expressed (P≤.05). Using qRT-PCR on a small, independent
sample of 5 cases and 5 controls we verified overexpression of the 3 highest expressing miRNAs among cases,
miR-18a, miR-181a, and miR-222; the differences were not statistically significant in this small set. The 21
differentially expressed miRNAs are known to target at least 82 genes; using the gene list for pathway analysis we
found enrichment of genes involved in cancer-related processes. In a separate case-case analyses restricted to the
21 miRNAs, we found 7 miRNAs with differential expression for women whose breast tumors differed by HER-2
expression, and 10 miRNAs with differential expression by nodal status.
Conclusions: miRNA levels in serum show a number of small differences between women who later develop
cancer versus those who remain cancer-free.
Introduction
MicroRNAs (miRNAs) are small, non-coding, single-
stranded RNAs ranging in size between 18 and 22
nucleotides; they are typically excised from longer, 60- to
110-nucleotide stem-loop precursors [1,2]. miRNAs
are involved in fundamental biological processes,
including development, differentiation, apoptosis, and
proliferation, and are believed to act predominately as
post-transcriptional regulators that can either degrade
their mRNA targets or repress their translation [3]. A
single miRNA may have multiple mRNA targets, and up to
30% of human genes may be regulated by miRNAs [4,5].
Aberrant expression of miRNAs in cancer was initially
identified in B-cell chronic lymphocytic leukemia [6],
and miRNA dysregulation has been subsequently
reported for many tumor types in which, depending on
the specific target mRNA(s), they may act either as
tumor suppressor genes or as oncogenes [7,8]. In breast
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cancer, post-diagnosis miRNA levels have been shown to
correlate with a number of tumor characteristics, including
stage, vascular invasion, proliferative index, and estrogen
receptor/progesterone receptor (ER/PR) status [9,10], and
may have prognostic value.
miRNAs have recently been found in human serum
and plasma, where they appear to be resistant to RNAase
degradation and thus relatively stable, even in stored
samples [11]. This stability has made miRNAs appealing
candidates for epidemiologic studies of stored samples,
particularly since miRNA profiling requires only small
amounts of serum or plasma [12]. The use of circulating
miRNA profiles as potential early-detection cancer mar-
kers has generated considerable interest [13-16], although
data addressing such application remain sparse. Initial
studies have suggested that serum levels of miRNAs may
differ between diagnosed cancer cases and controls [17],
and several recent case control studies of breast cancer
have reported evidence of differential miRNA expression
levels in serum [18-21]. These studies have shown little
agreement, perhaps because some have measured only a
few miRNAs whereas others have used more comprehen-
sive miRNA screens, but with a small number of subjects.
None has used samples obtained prior to diagnosis. Use
of such prospective samples avoids a number of impor-
tant potential biases (for example, differential selection
and processing of cases and controls or the possibility
that the differences observed in case samples are the
result of biopsy, cancer treatments, behavioral changes,
stress, or other factors experienced by cases but not
controls).
Here, we report on a study that prospectively collected
serum samples from 205 women who subsequently
developed breast cancer and 205 women who remained




The Sister Study [22] is a prospective cohort study of
50,884 women and was designed to examine the envir-
onmental and genetic determinants of breast cancer.
The cohort has been previously described [23]; briefly,
women from the US or Puerto Rico were eligible to
enroll if they themselves had never had breast cancer but
had a full or half-sister who had breast cancer. At base-
line interview, all participants provided extensive infor-
mation, including family history, reproductive history,
and information about potential risk factors. Informed
consent and blood samples were obtained during a home
visit. For women who subsequently developed breast
cancer, detailed information on diagnosis was collected
from medical records and self-report. Pathology reports
were abstracted for tumor grade, stage, and other
information, including status for ER, PR, and HER-2
(human epidermal growth factor receptor 2) expression.
The study was approved by the Institutional Review
Board of the National Institute of Environmental Health
Sciences, National Institutes of Health, and the Coper-
nicus Group Institutional Review Board.
Selection of cases and controls
We designed a matched-pair nested case control study.
We selected patients who had confirmed invasive breast
cancer, who completed enrollment by August 2008, and
whose diagnosis occurred within 18 months following
blood draw (n = 242). We excluded 29 cases who lacked
a serum sample or whose sample had integrity issues
during collection and shipping and eight cases whose
sample had limited volume, leaving 205 cases that are
the focus of our study. For each case, a matched control
was selected from the 50,884 participants on the basis
of the following criteria: no history of cancer (other
than non-melanoma skin cancer), having completed
enrollment by August 2008, an available blood sample,
same race (non-Hispanic white, black, Hispanic, or
other), similar age at enrollment (within 5 years), and
similar date of blood draw (within 2 months). Three
replicate serum samples from three women (nine samples
in total) who were not participants in the study but who
provided blood samples that were collected and pro-
cessed in the same manner as Sister Study participants
were used to provide technical replicates.
Assignment to extraction batches and array chip lot
To minimize possible processing and chip lot effects,
samples were assigned to processing batches of seven to
nine pairs, and batches had similar distributions of age,
race, and date of enrollment. For array hybridization,
each batch was assigned to one of two different chip
lots (’A’ and ‘B’) in a manner designed to ensure a balance
of these same characteristics. The nine replicates
(described above) were assigned to the same batch and
chip lot. Laboratory personnel were blind to case control
status and other phenotype information.
RNA extraction, labeling, and hybridization
Total RNA was extracted in batches by using a Total
RNA purification kit (cat. no. 17200; Norgen Biotek
Corp., Thorold, ON, Canada). In accordance with the
manufacturer’s recommendation not to exceed 200 µL
per column, 400 µL of total serum from each individual
was split into two equal 200-µL aliquots and then pro-
cessed separately following the manufacturer’s recom-
mended protocol for total RNA purification from
serum. An on-column DNase digestion was added
before sample elution by using an RNase-Free DNase I Kit
(cat. no. 25710; Norgen Biotek Corp.), and the two
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aliquots were subsequently pooled. Fixed volumes rather
than fixed amounts of RNA were used in accordance with
other studies [24].
Total RNA (8 µL) was directly labeled by using Flash
Tag Biotin HSR Labeling kits (cat. no. HSR30FTA;
Genisphere, LLC, Hatfield, PA, USA) in accordance with
the instructions of the manufacturer. RNA was heated to
80°C for 10 minutes before labeling to inactivate any
residual DNase activity. RNA was hybridized for 42
hours to the GeneChip miRNA 2.0 array (cat. no.
901755; Affymetrix Inc., Santa Clara, CA, USA [25]). The
GeneChip miRNA 2.0 arrays contain 100% miRBase
version 15 coverage of 131 organisms and contain probes
for 3,439 human non-coding RNAs (ncRNAs), including
1,105 miRNAs and 2,334 other ncRNAs (including
scaRNAs and snoRNAs). The arrays were washed and
stained by using standard Affymetrix protocols and
scanned by using an Affymetrix GCS 3000 7G Scanner.
Feature intensities were extracted by using miRNA 2.0
array library files. Array hybridization and scanning were
completed by Precision Biomarker Resources, Inc.
(Evanston, IL, USA). The average Spearman correlation
coefficient values for three sets of three technical repli-
cates were all above 0.8 (Additional file 1). Array data
were deposited into the NCBI Gene Expression Omnibus
(GSE44281).
Replication samples and qRT-PCR
An independent set of 10 women were used to validate
selected miRNAs via quantitative reverse transcription-
polymerase chain reaction (qRT-PCR). Five women who
provided consent and blood samples but who developed
breast cancer prior to completing enrollment were
selected as cases, along with five controls who also pro-
vided consent and blood samples and who were cancer-
free but did not complete enrollment. Total RNA was
extracted from serum samples of these women as
described above with the addition of Synthetic C. elegans
miScript miRNA Mimic (cat. no. MSY0000010; Qiagen,
Valencia, CA, USA). Synthetic cel-39 was spiked-in at a
final concentration of 0.25 fmol/µL prior to extraction
and used as a PCR normalization control. The RNA con-
centration, reverse transcription, and pre-PCR steps were
carried out in accordance with a previously published
protocol [26]. ExoSAP-IT (cat. no. 78250; Affymetrix
Inc.) treatment followed by column purification (cat. no.
28004; Qiagen) in accordance with the protocol of the
manufacturer was used to purify the pre-PCR product.
Individual PCR was run in triplicate by using 1 µL of
purified pre-PCR product. The reaction contained the
following components: 2x Taqman universal master mix
(cat. no. 4324018; ABI, Carlsbad, CA, USA), 1 µM
forward primer, 1 µM universal reverse primer, and
0.2 µM probe. The reaction was run on a Bio-Rad CFX
384 Real-Time System (Bio-Rad Laboratories, Inc.,
Hercules, CA, USA) by using the following parameters:
55°C for 2 minutes, 95°C for 10 minutes, followed by
40 cycles of 95°C for 15 seconds and 55°C for 1 minute.
PCR cycle threshold (Ct) values were recorded for each
target gene and for normalization controls and were
averaged across three independent runs. Primers for
miR-222, miR-181a, miR-1825, and miR-18a were cus-
tom-ordered from IDT (San Diego, CA, USA) by using
previously published sequences [26]. Primers for cel-39
were designed in the same fashion as above and custom-
ordered from IDT.
To determine the best candidate miRNA for PCR
normalization in our data set, we ran the array expression
data from the 47 miRNAs expressed in almost all indivi-
duals through the NormFinder software [27]. Norm-
Finder uses a model-based variance estimation approach
[28]. Using these results, we selected as a qRT-PCR nor-
malization control miR-1825, which showed one of the
highest stability values across the 410 cases and controls
and had blood levels that were similar to those of the
three target miRNAs. We used the average of miR-1825
and an external spike-in cel-39 control, a strategy shown
to be effective for controlling both technical and biologic
variability in qRT-PCR assays from serum [17,24]. The
efficiency of the four PCR assays (for miR-181a, miR-18a,
miR-222, and miR-1825) was similar for all four assays
(Additional file 2). Normalized relative expression was
based on Ct values and calculated as 1/(Ctgene−Ctnorm).
Data processing and statistical analysis
miRNA expression intensity values were background-
corrected and normalized across arrays by using the
robust multichip average method [29]. The intensity data
used in all analysis were log (2)-transformed.
For each array, the miRNA probe set signals were
compared with the distribution of signals for anti-genomic
probes that had matching GC content (miRNA QC Tool,
version 1.0.33.0), and in accordance with the recommen-
dation of the manufacturer, Wilcoxon rank-sum test of P
value of less than 0.06 was used to identify miRNAs above
background. Subsequent analysis was restricted to
414 miRNAs that exceeded background levels in at least
50 women. Conditional logistic regression was used to
identify differentially expressed miRNA probes between
cases and controls for those 414 probes. Because analysis
of circulating miRNAs in prospectively collected samples
is still exploratory, we - like some other investigators of
circulating miRNAs [30,31] - regard these results as
descriptive and not as tests of hypotheses and so provide
P values that are unadjusted for multiple comparisons.
The association between miRNAs and the tumor char-
acteristics of hormone receptor status (ER, PR, and
HER-2) and lymph node status was tested in a case-only
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logistic analysis, in which race was adjusted for. Chip lot
and batch were specified as random effect variables. All
statistical analyses were performed by using R 2.15.
Pathway analysis with ingenuity pathway analysis
miRNAs found to be significantly associated with case
control status were further analyzed with ingenuity path-
way analysis (IPA) [32]. Using IPA’s microRNA target
filter, we generated a list of predicted mRNA targets for
each of the 21 significant miRNAs. The list was then
restricted to the mRNAs listed in the IPA database as
experimentally verified targets of any of the 21 miRNAs.
This mRNA target list was then used to run a canonical
pathway analysis.
Results
A large number of miRNAs are detected in serum
In total, 410 serum samples from breast cancer cases
(n = 205) and controls (n = 205) were analyzed in this
study; baseline characteristics of the cases and controls
are summarized in Table 1. Of the 1,105 human miRNAs,
414 miRNAs were detected above background threshold
levels in at least 50 women. Forty-seven miRNAs were
detected above background in 400 or more women
(Table 2), and miR-16 showed the highest average exp-
ression. Even though expression of miRNAs showed con-
siderable inter-individual variation, several miRNAs,
including miR-1825 and miR-1228, were relatively con-
stant among women (Figure 1).
Discovery of differentially expressed miRNAs in serum
When paired case control analysis of the 414 miRNAs
expressed above background was used, 21 miRNAs
showed significantly different levels in cases and con-
trols (P ≤0.05) (Table 3). The differences were small,
ranging from 4% to 19%. Higher miRNA expression in
women destined to become cases was significantly more
common (16 of 21 miRNAs) than would be expected
by chance alone (binomial test, two-tailed P <0.05). Dif-
ferential miRNA expression was not stronger in women
close to their time of diagnosis, but sample size was
small and all cases were diagnosed within 18 months of
blood draw (data not shown). Using qRT-PCR on a small
independent replication set of five cases and five controls,
we further examined the three miRNAs (miR-18a, miR-
181a, and miR-222) with the highest expression in cases.
As predicted, all three miRNAs showed higher levels in
cases, although none was statistically significant in this
small set of women (Additional file 3).
The impact of miRNA alterations on regulatory pathways
To explore potential biological associations, we ran IPA
on the 82 experimentally verified mRNA targets of the 21
differentially expressed miRNAs. Sixteen IPA canonical
pathways, including molecular mechanisms of cancer,
were enriched as were other cancer-related pathways,
including p53 signaling, cyclins and cell cycle regulation,
and Myc-mediated apoptosis signaling (Additional file 4).
miRNA expression association with tumor characteristics
To investigate the potential association of serum miRNA
expression with tumor characteristics in the 205 women
who later developed breast cancer, we subclassified
them into groups based on tumor characteristics (Table 4)
and performed a case-case comparison. There was no
evidence of significant differences in serum miRNA
levels based on tumor ER or PR staining characteristics.
In comparisons of serum samples from the 25 women
who developed HER-2-positive tumors with 147 samples
from women who developed HER-2-negative tumors,
there were seven miRNAs with significantly differential
expression (P ≤0.05); one miRNA was overexpressed
and six miRNAs were underexpressed in the HER-
2-positive tumors (Figure 2A and Additional file 5).
Case-case comparison of serum from women who sub-
sequently developed lymph node-negative tumors (pN0,
n = 153) with that of women who developed lymph
node-positive tumors (pN1, pN2, or pN3, n = 52)
revealed 10 differentially expressed miRNAs (P ≤0.05);
five were overexpressed and five were underexpressed in
node-positive tumors (Figure 2B and Additional file 6).
Table 1 Demographic characteristics of study population









White (non-Hispanic) 179 179
Non-white 26 26
Table 2 Number of microRNAs detected above
background
Number of microRNAs
In at least 10 individuals 625
In at least 50 individuals 414
In at least 100 individuals 342
In at least 200 individuals 233
In at least 300 individuals 149
In at least 400 individuals 47
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Table 3 Twenty-one differentially expressed microRNAs with a P value of not more than 0
Expression microRNA P valuea Percentage change Previous reports in breast cancer tumor or cell lines
Overexpression miR-1255a 0.00 10 No data
miR-671-3p 0.01 7 No data
miR-1827 0.01 14 No data
miR-222 0.02 17 Overexpression [40,58,59]
miR-744 0.02 10 No data
miR-4306 0.03 8 No data
miR-151-3p 0.03 15 Overexpression [60]
miR-130b 0.03 14 Overexpression [61]
miR-363 0.03 11 No data
miR-149a 0.03 12 No data
miR-652 0.03 15 No data
miR-320d 0.04 14 No data
miR-18a 0.04 19 Overexpression [62-64]
miR-181a 0.05 15 Overexpression [38,65]
miR-3136 0.05 4 No data
miR-629 0.05 7 Overexpression [61]
Underexpression miR-548d-5p 0.01 −4 No data
miR-760 0.02 −9 No data
miR-1234 0.03 −9 No data
miR-18ba 0.04 −5 Underexpression [63]
miR-605 0.05 −7 No data
aConditional logistic regression was used to test for differential gene expression in 414 microRNAs (miRNAs) expressed above background.
Figure 1 A large number of microRNAs (miRNAs) are detected in serum. Box-and-whisker plots showing the log (2)-normalized expression
for the 47 miRNAs which are expressed above background in 400 individuals. Expression levels were adjusted for batch and chip lot across all
samples. The black line represents the median, and the upper and lower 25% are the top and bottom of the box, respectively. Dots represent
the outliers.
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Discussion
miRNA profiles are gaining interest as potential diagnostic
or prognostic markers for breast cancer [33]. However,
existing studies have been limited by sample size or the
number of miRNAs analyzed, and none has used prospec-
tively collected samples [18,31,34]. Our study minimized
potential biases by profiling global serum miRNA expres-
sion patterns in samples obtained from women prior to
clinical diagnosis (mean time to diagnosis was 10 months).
We found a set of 21 miRNAs differentially expressed in
serum samples from 205 women who subsequently devel-
oped breast cancer compared with 205 women who
remained cancer-free during the time of follow-up. The
differences in miRNA levels were small and include both
overexpression and underexpression of miRNAs in the
cases, and overexpression was significantly more frequent
than would be expected had the association been random.
Published reports of primary breast tumors or cell lines
have examined seven of the 21 differentially expressed
miRNAs we found, and all seven showed agreement with
the direction of change in our case serum samples (Table 3).
IPA of the mRNA targets of these differentially expressed
miRNAs suggested gene enrichment for cancer-related
signaling pathways. Although the absolute differences in
miRNA levels between serum samples of cases and con-
trols are quite small, differences pre-date clinical diagnosis
and may reflect important pathways for breast cancer
development.
miR-18a, miR-181a, and miR-222 showed the highest
percentage difference between cases and controls in our
study; qRT-PCR of these miRNAs in a small indepen-
dent replication set of cases and controls, though not
statistically significant, replicated the direction of change
for all three. These three miRNAs have been suggested
to act as oncogenes through regulation of their potential
target mRNAs. miR-18a is part of the oncogenic miR
17-92 cluster, which is often overexpressed in solid
tumors, including breast [35]. Overexpression of this
cluster is believed to cooperate with c-Myc in stimulating
proliferation by negatively regulating E2F1 [36,37].
Increased expression of miR-181a in the bone marrow of
patients with breast cancer has been reported to be asso-
ciated with shorter disease-free survival, higher grade,
and breast cancer recurrence [38]. miR-181a is believed
to target the tumor suppressor gene programmed cell
death protein 4 (PDCD4) [38], which inhibits tumor neo-
plastic transformation [39]. In breast cancer cell lines,
miR-222 overexpression has been reported to be asso-
ciated with tamoxifen resistance through targeting the
cell cycle inhibitor p27 (Kip1) [40]. miR-222 has also
been reported to increase proliferation of ERa-negative
cells while reducing the expression of various tumor sup-
pressor proteins [41], and expression of miR-222 has
been reported to increase cell migration in the epithelial-
to-mesenchymal transition acting downstream of the
RAS-RAF-MEK oncogenic pathway [42].
Interestingly, two recent case control studies have pro-
vided evidence that both miR-222 and miR-181a are
overexpressed in the serum of patients with breast cancer.
One used sequencing by oligonucleotide ligation and
detection (SOLiD) of serum samples obtained prior to sur-
gery from 13 breast cancer cases compared with samples
from 10 healthy controls and found 26 miRNAs that were
overexpressed in cases, including miR-222 and miR-181a;
overexpression of miR-222 was validated in an indepen-
dent group of 50 cases and 50 controls by using qRT-PCR
[20]. A second study used Solexa sequencing combined
with Taqman low-density array chips on serum samples
obtained prior to surgery from 48 breast cancer cases and
Table 4 Patient tumor characteristics


















III or higher 13 6.34










No overexpression 147 71.71
Overexpression 25 12.20
Missing 33 16.10
Breast cancer staging in the Sister Study used a modification of TNM 7 [66].
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48 controls; 10 miRNAs were found to be overexpressed
in the cases, and four were validated by using qRT-PCR in
an independent group of 76 cases and 76 controls [21].
That study also found overexpression of miR-222 [21].
These studies, combined with our prospective study, pro-
vide a growing body of evidence that miR-222 measured
in blood is associated with breast cancer.
Among cases, we compared the serum miRNA profiles
of women with different tumor characteristics, including
hormone status (ER, PR, and HER-2) and nodal status.
Although there were no differences in ER or PR status,
there were differences in HER-2 and lymph node status.
Of the seven miRNAs differentially expressed in the
serum of women who developed HER-2-overexpressing
breast tumors, miR-93, miR-183, and miR-29a have
been reported to be associated with breast cancer in
previous studies [20,43,44]. In our study, miR-93 was
underexpressed in the serum of women who developed
HER-2-overexpressing breast tumors; interestingly,
miR-93 expression was recently shown to induce a more
differentiated cell phenotype in breast cancer cell lines,
and expression of miR-93 in mouse mammary fat pads
blocked tumor development and metastases [44]. Of the
10 miRNAs differentially expressed in the serum of
women with tumors that spread to the lymph nodes
(pN1 or higher), four (miR-145, miR-124, miR-125b,
and miR-320) have been reported to be associated with
breast cancer in previous studies [45-48]. Of these,
miR-320 is of particular interest as we found three miR-320
family members (miR-320b, miR-320d, and miR320e) to
be underexpressed in the serum of women who developed
lymph node-positive breast tumors. miR-320 has been
Figure 2 Serum microRNA (miRNA) expression is associated with tumor subtype. (A) Serum miRNAs significantly associated with HER-2
expression (negative differences correspond to lower levels in women developing tumors with overexpression) (P ≤0.05). (B) Serum miRNAs
significantly associated with nodal status (pN1 or higher versus pN0) (P ≤0.05). P values and percentage change were determined by using a
linear mixed model.
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reported to be decreased in breast tumor tissue and down-
regulation of miR-320 - through loss of phosphatase and
tensin homolog (PTEN) -has been shown to promote
tumor proliferation and invasiveness in mouse models;
expression of miR-320 distinguished human normal breast
stroma from tumor stroma and was correlated with recur-
rence [49]. A study comparing miRNA expression in
inflammatory breast cancer (IBC) with non-IBC also
found miR-320 to be downregulated in the more aggres-
sive IBC group of tumors [50]. Thus, loss of miR-320
expression may be associated with a higher likelihood of
lymph node involvement and a more aggressive metastatic
phenotype.
Although miRNAs that are differentially expressed
between tumor and normal tissue are more frequently
downregulated in tumor tissue [7], our study (like others
[20,21]) has found that circulating miRNAs that differ in
levels between breast cancer patients and controls are
more frequently at higher levels in case blood samples.
The mechanism underlying circulating miRNA stability
is still being investigated. One model involves the active
release of miRNAs from cells in membrane-bound
microvesicles, including exosomes and shedding vesicles
[51-53]. There is evidence that microvesicles can deliver
miRNAs to recipient cells and trigger changes in target
mRNA levels [54]. A recent report has shown that vesicle-
encapsulated miRNAs represent only a minor portion of
circulating miRNAs but that a significant portion of cir-
culating miRNAs are associated with Argonaute2 (Ago2)
[55], the effector component of the miRNA-induced
silencing complex [56]. Both models support the possi-
bility that miRNAs may be actively released into circula-
tion and could act as signaling molecules able to regulate
their target mRNA expression in recipient cells. Cancer-
associated miRNAs in the circulation could also originate
from immunocytes in the tumor microenvironment or
from a response mediated by the body’s systemic response
to disease [57].
Conclusions
We find some evidence of differences in miRNA serum
levels between women who subsequently developed cancer
compared with women who remained clinically cancer-
free. The magnitude of these differences is small, and this
may limit their clinical application as circulating early-
detection markers for breast cancer. This is the first study
to use prospectively collected samples; limitations include
a relatively short follow-up period and a sample size that
is not large enough to fully explore etiologic versus diag-
nostic relevance. Our study was carried out within a
cohort of women who each had a sister with breast cancer,
putting the former at about twofold increased risk, and so
the differences that we observed may not be generalizable
to women without a similar family history.
Additional material
Additional file 1: Spearman correlation coefficient values for
technical replicates of arrays. Three replicate serum samples from
three women (nine samples in total) were processed and hybridized to
arrays as described for samples in the main study. Spearman correlation
coefficients were calculated for the three pairings of replicate samples for
each woman and averaged. One array from Individual 1 appeared to be
an outlier but was included in the results shown above. Exclusion of this
array resulted in correlation coefficients of greater than 0.97 in all three
categories of probes for Individual 1.
Additional file 2: Efficiency of the four polymerase chain reaction
(PCR) assays. The efficiency of PCR amplifications for the normalization
control and three target microRNAs (miRNAs) was calculated by using
DART-PCR version 1.0. The average efficiency of each of three
independent PCRs was similar across all four miRNAs.
Additional file 3: Quantitative reverse transcription-polymerase
chain reaction (qRT-PCR) validation in 10 cases and controls. Serum
levels of five cases and five controls were examined by using qRT-PCR
for miR181a, miR18a, and miR-222. Box plots show normalized relative
expression. Normalization was carried out by using the mean of miR-
1825 and spiked in cel-39. The horizontal line represents the mean for
each sample.
Additional file 4: Experimentally observed targets enriched for
cancer and signaling pathways. Identified ingenuity pathway analysis
(IPA) canonical pathways enriched by the experimentally observed
targets of the 21 miRNAs differentially expressed between the cases and
non-cases. The negative log (10) false discovery rate-corrected P values
are shown. Note that this test has not corrected for possible
dependencies across the mRNAs considered and that statistical
significance may be overstated. HER-2, human epidermal growth factor
receptor 2; ILK, integrin-linked kinase; PTEN, phosphatase and tensin
homolog.
Additional file 5: List of differentially expressed serum microRNAs
(miRNAs) based on HER-2/NEU expression.
Additional file 6: List of differentially expressed serum microRNAs
(miRNAs) based on nodal status.
Abbreviations
ER: estrogen receptor; HER-2: human epidermal growth factor receptor 2;
IBC: inflammatory breast cancer; IPA: ingenuity pathway analysis; miRNA:
microRNA; ncRNA: non-coding RNA; PCR: polymerase chain reaction; PR:
progesterone receptor; qRT-PCR: quantitative reverse transcription-
polymerase chain reaction.
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